Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
31.2M
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
15.2M
-
Shares change
-
+535K
-
Total reported value, excl. options
-
$191M
-
Value change
-
+$6.82M
-
Number of buys
-
31
-
Number of sells
-
-7
-
Price
-
$12.69
Significant Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q1 2023
42 filings reported holding ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2023.
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.2M shares
of 31.2M outstanding shares and own 48.75% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (4.81M shares), PERCEPTIVE ADVISORS LLC (3.01M shares), Sands Capital Ventures, LLC (1.65M shares), CITADEL ADVISORS LLC (1.64M shares), WELLINGTON MANAGEMENT GROUP LLP (888K shares), FEDERATED HERMES, INC. (614K shares), MARSHALL WACE, LLP (597K shares), NEA Management Company, LLC (482K shares), BlackRock Inc. (474K shares), and VANGUARD GROUP INC (409K shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.